NEW YORK, Oct. 6, 2016 /PRNewswire/ -- Attorney Advertising
-- Bronstein, Gewirtz & Grossman, LLC is investigating
potential claims on behalf of purchasers of the securities Mylan
N.V. ("Mylan" or the "Company") (NASDAQ: MYL). Such investors
are advised to contact Peretz
Bronstein or his Investor Relations Analyst, Yael Hurwitz at info@bgandg.com or
212-697-6484.
The investigation concerns whether Mylan and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934
On October 5, 2016, the Centers
for Medicare and Medicaid Services ("CMS") published a report
stating that for years Mylan had overcharged the U.S. Medicaid
health program for its EpiPen shot, despite being to provide
greater discounts under the law. The CMS letter stated that
from 2011 to 2015, the U.S. Medicaid health program spent close to
$797 million on EpiPens, including
rebates of about 13%, instead of the 23.1% discount that the U.S.
should have received. The letter also said that the
government has "expressly told Mylan that the [EpiPen] product is
incorrectly classified." Following this news, Mylan stock
dropped $1.19 per share, or 3.13%, to
close at $36.84 on October 6, 2016.
If you are aware of any facts relating to this investigation, or
if you purchased shares of Mylan, you can assist this investigation
by visiting the firm's site: http://www.bgandg.com/myl or by
contacting Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC at
212-697-6484 or via email info@bgandg.com. Those who inquire
by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-mylan-nv-myl-300341013.html
SOURCE Bronstein, Gewirtz & Grossman, LLC